investigational new drug (IND)
FDA accepts IND application for UK biotech’s antibacterial drug candidate
Clinical stage biotechnology company, Destiny Pharma, has announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for its lead clinical drug candidate, XF-73. Read more
FDA accepts IND application allowing InflaRx to initiate Phase IIb study
The FDA has accepted an IND application by biopharmaceutical company, InflaRx, which will enable the company to initiate a Phase IIb study evaluating the efficacy and safety of IFX-1 in patients with moderate or severe Hidradenitis Suppurativa. Read more
Sernova receives notice of allowance from FDA for its investigational new drug
Clinical-stage company, Sernova has received a notice of allowance from the US Food and Drug Administration (FDA) for its investigational new drug (IND), with which it will initiate a clinical trial of its Cell Pouch System (CPS) in the US. Read more
FDA approves Phase Ib/IIa study of GNS561 for treatment of liver cancer
Genoscience Pharma has announced that initiation of a Phase Ib/IIa study of its most advanced compound, GNS561, for the treatment of patients with advanced hepatocarcinoma (HCC), has received approval from the US Food and Drug Administration (FDA). Read more
